Morning Movers & Moonshots: VirnetX Rockets, Carbon Revolution Accelerates, and Disc Medicine Grabs FDA’s Fast Track

October 17, 2025

DENVER, Colo., Oct 17, 2025 (247marketnews.com)- With a mix of surprise catalysts, bullish momentum, today’s tape tells a compelling story of disruption and acceleration.

Carbon Revolution (NASDAQ:CREV) accelerated sharply after announcing new interest in its lightweight carbon fiber wheels, a technology poised to disrupt traditional auto manufacturing. With volume surging, the company is benefiting from EV tailwinds and efficiency mandates, as OEMs seek to improve range and performance through weight reduction.

Disc Medicine (NASDAQ:IRON) received the first-ever Commissioner’s National Priority Voucher (CNPV) from the FDA for its EPP treatment bitopertin, potentially cutting the review process to just 1–2 months. With Orphan Drug and Rare Pediatric Disease designations already in hand, Disc (NASDAQ:IRON) is now targeting accelerated approval in a debilitating sun-sensitivity disorder that impacts quality of life for thousands. CEO John Quisel emphasized the urgency: “The need for a new therapy… is immense.”

SEALSQ (NASDAQ:LAES) unveiled its Quantum-Resistant ASIC (QASIC) strategy, leveraging its acquisition of IC’Alps to become the only company offering catalog ICs, custom ICs, and security IP in one package. CEO Carlos Moreira called the move a “historic milestone” as SEALSQ positions itself at the center of post-quantum hardware security, with applications spanning defense, AI, IoT, and beyond.

ESS Tech (NYSE:GWH) gained double digits as investors digested renewed interest in long-duration energy storage. As grid stability becomes a critical issue globally, ESS’s iron flow battery tech is gaining traction in policy circles and clean energy roadmaps. Over 8.4 million shares traded, signaling potential institutional rotation into the name.

VENU (NYSE:VENU) continues to climb on investor excitement over its Sunset Amphitheater plans and $23M FireSuite sales blitz. Backed by music star Dierks Bentley and NFL legend Troy Aikman, VENU is emerging as an infrastructure powerhouse in live entertainment. CEO J.W. Roth’s ambition is clear: he’s reimagining what’s possible for the fan experience.

Praxis Precision (NASDAQ:PRAX) is following through after announcing positive topline results from two pivotal Phase 3 studies of ulixacaltamide, its investigational treatment for essential tremor (ET). In Study 1, patients saw a 4.3-point improvement in mADL11 at Week 8 (p<0.0001), with all key secondary endpoints also meeting statistical significance. In Study 2, a randomized withdrawal design, showed 55% of ulixacaltamide-treated patients maintained response, compared to 33% on placebo (p=0.0369).

Praxis has submitted a pre-NDA meeting request with the FDA, eyeing a 2026 NDA filing. With a strong safety profile and demand reflected in 200,000+ study volunteers, the data positions ulixacaltamide as a first-in-class CNS breakthrough.

Please click here to read Cenorium’s full Venu analyst report on 247marketnews.com.

For the full 24/7 Market News VENU report and in-depth insights, including analyst reports, visit: Read 24/7 Market News VENU Report/

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

24/7 MARKET NEWS, INC (247) Disclaimer and Disclosure
PAID EDITORIAL DISCLOSURE: 247MarketNews.com has been compensated $2,500 per week by MicroCap Strategies for ongoing press and editorial coverage of VENU. This is a paid editorial communication intended for informational purposes only. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. This press release may include technical analysis for informational purposes only and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (CREV, IRON, LAES, GWH, VENU, PRAX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.